RxDoctor Payments Data

Kamilah Jones

Family · Arlington, TXNPI 1265997423

Payments from drug & device makers

$2,010in general payments, 2019–2025

Across 74 payments — averaging $27.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$801
  • Lilly USA, LLC$218
  • Novo Nordisk$201
  • AstraZeneca$127
  • Spinal Simplicity, LLC$104
  • AbbVie$98
  • plus $460 from 17 others

What the payments were for

  • Travel & lodging$52126%
  • Food & beverage$1,48974%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,010 in reported general payments places this provider in the 80th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$49,385
Medicare patients
108
Services billed
535

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZtlidoLidocaine61$21,177
BelbucaBuprenorphine Hcl35$21,064
Lidocaine166$19,053
MovantikNaloxegol Oxalate29$11,710
Aimovig AutoinjectorErenumab-Aooe14$10,726
Pregabalin205$9,752
Buprenorphine42$8,131
Gabapentin542$6,778
Tizanidine Hcl818$5,423
Diclofenac Sodium130$5,019
Acetaminophen-CodeineAcetaminophen With Codeine195$3,942
Etodolac86$2,534
Cyclobenzaprine Hcl201$2,095
Tramadol Hcl273$1,959
Amitriptyline Hcl112$1,335

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Scilex Pharmaceuticals Inc.Ztlido$83$21,17761 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 15,456 family providers in Texas.

Other family in Arlington

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →